U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H37ClO7
Molecular Weight 521.0432
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BECLOMETHASONE DIPROPIONATE

SMILES

CCC(=O)OCC(=O)[C@]1([C@@]([H])(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@@]21C)O)Cl)OC(=O)CC

InChI

InChIKey=KUVIULQEHSCUHY-XYWKZLDCSA-N
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1

HIDE SMILES / InChI
Molecular Formula C28H37ClO7
Molecular Weight 521.0432
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

1976
94
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.419 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12107606/
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.985 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12107606/
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12107606/
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Disc. AE: Epistaxis, Increased intraocular pressure...
AEs leading to
discontinuation/dose reduction:
Epistaxis (5 patients)
Increased intraocular pressure (1 patient)
Colon cancer (2 patients)
Nasal septum ulceration (2 patients)
Nasal discomfort (2 patients)
Sinusitis (2 patients)
Nasal congestion (1 patient)
Headache (1 patient)
Nasal mucosal disorder (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Disc. AE: Sinusitis, Nasopharyngitis...
AEs leading to
discontinuation/dose reduction:
Sinusitis
Nasopharyngitis
Nasal congestion
Headache
Infection respiratory
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
AEs

AEs

AESignificanceDosePopulation
Headache 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Increased intraocular pressure 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal congestion 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal mucosal disorder 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Colon cancer 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal discomfort 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal septum ulceration 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Sinusitis 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Epistaxis 5 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Headache Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Infection respiratory Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal congestion Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasopharyngitis Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Sinusitis Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B3-032489
http://www.3bsc.com/index/pro_info.php?id=53753
AHH Chemical co.,ltd
MT-27153
http://www.ahhchemical.com/product/MT-27153.html
Chem Scene
CS-0120927
http://www.chemscene.com/5534-18-9.html
Chemspace
CSSB00020661129
https://chem-space.com/CSSB00020661129
LGC Standards
LGCFOR0199.01
https://www.lgcstandards.com/US/en/p/LGCFOR0199.01
LGC Standards
MM0199.01-0025
https://www.lgcstandards.com/US/en/p/MM0199.01-0025
Lab Network
LN01274417
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01274417
MedChem Express
HY-136239
https://www.medchemexpress.com/beclomethasone-17-propionate.html
MolPort
MolPort-006-116-979
https://www.molport.com/shop/molecule-link/MolPort-006-116-979
Smolecule
S600542
https://www.smolecule.com/products/s600542
THE BioTek
bt-307443
https://www.thebiotek.com/product/others/bt-307443
eNovation Chemicals
D700538
https://www.enovationchem.com/ProductDetails.asp?ProductID=D700538
PubMed

PubMed

TitleDatePubMed
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids.
2006 Mar
Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.
2010 Oct 1
Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway.
2011 Dec
Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.
2013
Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes.
2013 May
Patents

Patents

20020106401
2
JP2005097221A
8
JPS597117A
3
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:36 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:36 UTC 2021
Record UNII
5B307S63B2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BECLOMETHASONE DIPROPIONATE
MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
TOPSTER
Common Name English
PROPADERM FORTE
Common Name English
NSC-755901
Code English
SCH 8020W
Code English
QNASL
Common Name English
INALONE R
Common Name English
SGX-203
Code English
BECLOMETASONE DIPROPIONATE, ANHYDROUS [EP]
Common Name English
BECLOMETASONE DIPROPIONATE [WHO-DD]
Common Name English
BECLOMETASONE DIPROPIONATE [JAN]
Common Name English
QVAR
Brand Name English
BECLOMETASONE DIPROPIONATE
WHO-DD   WHO-IP  
Common Name English
BECLOMETHASONE DIPROPIONATE [ORANGE BOOK]
Common Name English
BELCHLORHINOL
Common Name English
VANCENASE AQ
Common Name English
NASOBEC
Common Name English
BECLOMETHASONE DIPROPIONATE [MI]
Common Name English
BECLOMETHASONE 17,21-DIPROPRIONATE
Common Name English
VENTOLAIR
Common Name English
BETAMETHASONE DIPROPIONATE IMPURITY E
Common Name English
BECLOMETASONE DIPROPIONATE ANHYDROUS
Common Name English
BECONASE
Brand Name English
BECLOMETHASONE DIPROPIONATE [USP MONOGRAPH]
Common Name English
ORBEC
Common Name English
ENTYDERMA
Common Name English
SGX-202
Code English
SGX-201
Code English
BECLOVENT
Brand Name English
ORBESHIELD
Brand Name English
SCH-18020W
Code English
SANASTHMAX
Common Name English
BECLOMETHASONE DIPROPIONATE [USAN]
Common Name English
SANASTHYMYL
Common Name English
SCH 18020W
Code English
CLENIL A
Common Name English
BECLOMETASONE DIPROPIONATE, ANHYDROUS
EP  
Common Name English
BECLOMETASONI DIPROPIONAS [WHO-IP LATIN]
Common Name English
9-CHLORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17,21-DIPROPIONATE
Common Name English
VANCENASE
Brand Name English
BECLOMETASONE DIPROPIONATE [EP MONOGRAPH]
Common Name English
BECLOMETHASONE 17,21-DIPROPIONATE
Common Name English
BECLOMETHASONE DIPROPIONATE [USP-RS]
Common Name English
SERNIVO
Brand Name English
VANCERIL
Brand Name English
BECLOMETASONE DIPROPIONATE [WHO-IP]
Common Name English
KORBUTONE
Common Name English
BECLOMET
Brand Name English
BECLOMETHASONE DIPROPIONATE [VANDF]
Common Name English
BECLOMETHASONE DIPROPIONATE [USP]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-CHLORO-11-HYDROXY-16-METHYL-17,21-BIS(1-OXOPROPOXY)-, (11.BETA.,16.BETA.)-
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 356311
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
FDA ORPHAN DRUG 111198
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
FDA ORPHAN DRUG 146501
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
FDA ORPHAN DRUG 144201
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
FDA ORPHAN DRUG 285609
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
Code System Code Type Description
FDA UNII
5B307S63B2
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
DRUG CENTRAL
294
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BECLOMETHASONE DIPROPIONATE
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY Description: A white to creamy white powder; odourless. Solubility: Practically insoluble in water; soluble in 60 parts of ethanol (~750 g/l) TS. Category: Antiasthmatic drug. Storage: Beclometasone dipropionate should be kept in a well-closed container, protected from light. Definition: Beclometasone dipropionate contains not less than 96.0% and not more than 104.0% of C28H37ClO7, calculated with reference to the dried substance.
DRUG BANK
DB00394
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
EVMPD
SUB00681MIG
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
RXCUI
1348
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY RxNorm
IUPHAR
5894
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200500
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
ECHA (EC/EINECS)
226-886-0
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
EPA CompTox
5534-09-8
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
USP_CATALOG
1048506
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
BECLOMETASONE DIPROPIONATE
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
NCI_THESAURUS
C299
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
EVMPD
SUB26515
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
CAS
5534-09-8
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
PUBCHEM
21700
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY
MERCK INDEX
M2287
Created by admin on Fri Jun 25 21:02:36 UTC 2021 , Edited by admin on Fri Jun 25 21:02:36 UTC 2021
PRIMARY Merck Index
Related Record Type Details
GLUCOCORTICOID RECEPTOR
TARGET -> AGONIST
Structure of BECLOMETHASONE DIPROPIONATE, CYCLO-3'-.BETA.-
DEGRADENT -> PARENT
Structure of BECLOMETHASONE DIPROPIONATE, CYCLO-3'-.ALPHA.-
DEGRADENT -> PARENT
Structure of BECLOMETHASONE DIPROPIONATE MONOHYDRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of BECLOMETHASONE
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA
Structure of BECLOMETASONE 21-PROPIONATE
PARENT -> METABOLITE LESS ACTIVE
Structure of BECLOMETHASONE 17-MONOPROPIONATE
METABOLITE ACTIVE -> PRODRUG
MAJOR
PLASMA
Structure of BECLOMETASONE 21-PROPIONATE
METABOLITE LESS ACTIVE -> PARENT
Related Record Type Details
Structure of BETAMETHASONE 9,11-EPOXIDE 21-PROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BETAMETHASONE 9,11-EPOXIDE 17,21-DIPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BETAMETHASONE 9,11-EPOXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BECLOMETHASONE 17-MONOPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BETAMETHASONE 9,11-EPOXIDE 17-PROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-BROMO-BECLOMETHASONE DIPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BETAMETHASONE DIPROPIONATE
PARENT -> IMPURITY
http://apps.who.int/phint/pdf/b/Jb.6.1.43.pdf
Structure of 9-CHLORO-11.BETA.-HYDROXY-16.BETA.-METHYL-3,20-DIOXOPREGNA-4,6-DIENE-17,21-DIYL DIPROPANOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.ALPHA.-CHLORO-BECLOMETHASONE DIPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BECLOMETHASONE 21-ACETATE 17-PROPIONATE
IMPURITY -> PARENT
Structure of 9-DESCHLORO-9-BROMO-BECLOMETHASONE DIPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9,11.BETA.-DICHLORO-16.BETA.-METHYL-3,20-DIOXOPREGNA-1,4-DIENE-17,21-DIYL DIPROPANOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 16.BETA.-METHYL-3,20-DIOXOPREGNA-1,4-DIENE-17,21-DIYL DIPROPANOATE
IMPURITY -> PARENT
Structure of 6.ALPHA.-BROMO-BECLOMETHASONE DIPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BECLOMETHASONE DIPROPIONATE 11-PROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BECLOMETHASONE 21-BUTYRATE 17-PROPIONATE
IMPURITY -> PARENT
Structure of 1,2-DIHYDRO-BECLOMETHASONE DIPROPIONATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 16.BETA.-METHYL-3,20-DIOXOPREGNA-1,4,9(11)-TRIENE-17,21-DIYL DIPROPANOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of BECLOMETHASONE 17-MONOPROPIONATE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966